Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET

Center for Addiction and Mental Health (CAMH)

Status and phase: Completed; Phase 2; Phase 1

Conditions: Tobacco Use Cessation; Smoking Cessation

Treatments: Drug: Buspirone; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01699828

186/2011

Details and patient eligibility

About

The objective of the present study is to use positron emission tomography brain imaging to investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin partial agonist but has recently been identified as a D3 antagonist. It is hypothesized that clinically relevant doses of buspirone will occupy the D3 receptor.

Full description

Buspirone is used for anxiety disorder treatment, a therapeutic effect that has been thought to be mediated through its partial agonist properties at the serotonin receptor. However, since one PET study in humans has shown low occupancy of the serotonin by buspirone in clinical doses and since the DRD3 has been recently implicated in anxiety, some therapeutic effects of buspirone may be mediated through the DRD3. In human clinical studies, promising effects of buspirone have been reported for treatment of substance dependence, including tobacco, marijuana, and opiates, and clinical studies in cocaine dependent subjects are underway. However, it is unclear if buspirone is producing those effects through the DRD3 and no human study has incorporated a PET imaging component to investigate this question; it remains unclear whether buspirone significantly occupies the DRD3 at therapeutic doses in humans.

Enrollment: 6 patients

Sex: All

Ages: 19 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 19 years or older

Exclusion criteria

• Medical condition including cardiovascular, renal, hepatic or cerebrovascular diseases
• History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor, - Present or past psychiatric condition including mood, anxiety, psychotic disorders and substance abuse and/or dependence.
• Condition that precludes use of buspirone or that will interfere with participation in the present study (such as hypersensitive to buspirone hydrochloride).
• Pregnancy or breastfeeding.
• Presence of metal objects in the body or implanted electronic devices, that preclude safe MR scanning.
• Claustrophobia.
• Current use or use during the previous month of medication that may affect the CNS, including monoamine oxidase inhibitor (MAOI) or positive during drug screening for drugs of abuse or any medication that could increase the risk of buspirone administration.
• Exposure to radiation in the last 12 month exceeding permissible limit for subjects participating in research.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

6 participants in 4 patient groups, including a placebo group

Buspirone 120 mg

Experimental group

Description:

Buspirone 120 mg (encapsulated).

Treatment:

Drug: Buspirone

Buspirone 60 mg

Experimental group

Description:

Buspirone 60 mg (encapsulated)

Treatment:

Drug: Buspirone

Placebo

Placebo Comparator group

Description:

Placebo (encapsulated)

Treatment:

Drug: Placebo

Buspirone 30 mg

Experimental group

Description:

Buspirone 30 mg (encapsulated).

Treatment:

Drug: Buspirone